The PharmaTimes Clinical Researcher of the Year – The Americas 2025 Awards offer an unparalleled opportunity to showcase your expertise, gain recognition, and accelerate your career in clinical ...

Santen has announced that the European Commission has granted market authorisation for Ryjunea, a low-dose atropine eye drop (0.1 mg/ml), to slow the progression of paediatric myopia. This approval ...

Birmingham spin-out Linear Diagnostics has secured £1m funding to advance a rapid test for sexually transmitted infections (STIs), working in partnership with the NIHR HealthTech Research Centre (HRC) ...

Sogroya acts as a replacement for endogenous growth hormone and is administered once a week to support growth in children with the condition. NICE’s recommendation provides families and healthcare ...

The National Institute for Health and Care Excellence (NICE) has published updated guidance recommending Forxiga (dapagliflozin) as a treatment option for chronic kidney disease (CKD) in a broader ...

Flip feasibility: from capacity and capability to human realities True feasibility begins with understanding the patient. That means assessing not just clinical eligibility, but patient motivation, ...

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending mirikizumab (Omvoh) for adults with moderately to severely active Crohn’s disease who have not ...

The great NHS prescribing lottery. Imagine a patient in Manchester receiving a cutting-edge medication, while another in Cornwall waits endlessly for the same treatment. Welcome to the NHS prescribing ...

Richard Condon, CEO Aspire Pharma, discusses successful leadership ...

Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid medicines to treat pain and other neuronal ...

The National Institute for Health and Care Excellence (NICE) has recommended FILSPARI (sparsentan) for use in the NHS in England as a treatment for primary IgA nephropathy. The decision follows UK ...

With over 55 million people worldwide living with dementia, Oxford Brain Diagnostics (OBD) is set to revolutionise early diagnosis with its patented Cortical Disarray Measurement (CDM®) technology.